| Treatment Class | Specific Agent/Intervention | Mechanism of Action | Administration Route and Frequency | Efficacy Endpoints | Safety Profile / Adverse Events | MAXO Term Suggestion |
|---|---|---|---|---|---|---|
| GnRH agonist depot | Leuprolide acetate 6-month depot, 45 mg | Continuous GnRH receptor stimulation causes pituitary desensitization, suppressing LH/FSH release and downstream gonadal sex steroid production, thereby halting premature HPG-axis activation (pqac-00000007) | Intramuscular depot at weeks 0 and 24; 2 injections over 48 weeks in the phase 3 trial (pqac-00000007) | Week-24 peak-stimulated LH suppression <4 mIU/mL in 86.7% (39/45); through 48 weeks, LH suppression in ≥86.7%, estradiol suppression in ≥97.4% of girls, testosterone suppression in 100% of boys; physical signs suppressed at week 48 in 90.2% of girls and 75.0% of boys; bone age advanced more slowly than chronological age; height velocity declined in treatment-naive children from 10.1 to 6.5 cm/year by week 20 (pqac-00000007) | No new safety signals identified; no adverse event led to discontinuation; overall safety profile consistent with other GnRH agonist formulations (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| GnRH agonist depot | Leuprolide acetate 1-month IM depot | Same class mechanism: chronic GnRH agonist exposure suppresses pituitary gonadotropin secretion and sex steroid production to arrest pubertal progression (pqac-00000007) | Intramuscular, monthly; described as an available CPP formulation (pqac-00000007) | Treatment goals for GnRHa therapy include suppression of LH and sex hormones, cessation of pubertal development, and normalization of bone-age advancement to preserve adult height (pqac-00000007) | Specific formulation-level adverse-event data not detailed in gathered texts; class adverse effects generally monitored include injection-site reactions and treatment-emergent symptoms during suppression therapy (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| GnRH agonist depot | Leuprolide acetate 3-month IM depot | Same class mechanism; sustained agonist exposure desensitizes pituitary GnRH receptors (pqac-00000007) | Intramuscular, every 3 months; referenced as an approved available formulation for CPP (pqac-00000007) | Same class efficacy goals: biochemical suppression of pubertal gonadotropins and sex steroids, slowing bone-age progression, and preservation of adult height potential (pqac-00000007) | Specific trial data not provided in retrieved texts; safety considered part of established GnRHa class experience (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| GnRH agonist depot | Leuprolide acetate 6-month subcutaneous depot | Same class mechanism; long-acting GnRH agonist suppression of HPG axis (pqac-00000007) | Subcutaneous depot, every 6 months; listed among currently available formulations (pqac-00000007) | Same class efficacy goals: LH and sex-steroid suppression, stabilization/regression of pubertal signs, slowing skeletal maturation (pqac-00000007) | Specific safety outcomes not detailed in retrieved texts; class monitoring includes injection-site and general treatment adverse events (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| GnRH agonist depot | Triptorelin pamoate 1-month IM depot | Same class mechanism; continuous GnRH agonism suppresses pulsatile gonadotropin release (pqac-00000007) | Intramuscular, monthly; identified as an available CPP option (pqac-00000007) | Used to achieve standard CPP treatment targets: LH/FSH and sex-steroid suppression, arrest of pubertal progression, and improved height prognosis (pqac-00000007) | Specific adverse-event profile not detailed in retrieved texts (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| GnRH agonist depot | Triptorelin pamoate 6-month IM depot | Same class mechanism; pituitary desensitization after continuous receptor stimulation (pqac-00000007) | Intramuscular, every 6 months; identified as an available CPP option (pqac-00000007) | Same CPP efficacy targets as other depot GnRHa formulations (pqac-00000007) | Specific formulation-level safety data not detailed in retrieved texts (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| GnRH agonist implant | Histrelin acetate implant | Continuous release of GnRH agonist suppresses pituitary gonadotropin release and sex steroid production (pqac-00000007) | Subcutaneous implant, approximately 12-month duration; listed as currently available (pqac-00000007) | Same intended endpoints as other GnRHa modalities: biochemical suppression, halting pubertal progression, slowing bone-age advancement, preserving adult height potential (pqac-00000007) | Specific adverse-event details not given in retrieved texts; implant-related procedural and local adverse events are typically monitored in practice (pqac-00000007) | MAXO: gonadotropin-releasing hormone agonist therapy |
| Monitoring / biomarker adjunct | Serum kisspeptin and DLK1 monitoring during GnRH analog treatment | Biomarker-based monitoring rather than treatment itself; GnRH analog therapy lowered median kisspeptin and increased median DLK1 after 6 months in girls with CPP, suggesting potential treatment-monitoring utility (pqac-00000008) | Blood testing at baseline and after 6 months of GnRH analog treatment in the reported prospective study (pqac-00000008) | Baseline kisspeptin and DLK1 were not reliable for differentiating CPP from premature thelarche, but dynamic change during therapy may help monitor response (pqac-00000008) | No treatment-related safety signal from the biomarker study itself; this is an adjunctive monitoring strategy (pqac-00000008) | MAXO: laboratory biomarker monitoring |
| Treatment strategy | Individualized long-acting GnRHa selection | Therapeutic strategy centers on choosing a long-acting GnRH agonist formulation suited to patient needs while maintaining HPG-axis suppression (pqac-00000007) | Choice among monthly, 3-month, 6-month depot, or 12-month implant options depending on patient and caregiver preference, access, and tolerability (pqac-00000007) | Core targets across formulations: suppress LH and sex hormones, stop or regress pubertal signs, reduce bone-age advancement, and preserve adult height; patient/parent-reported outcomes remained stable in the leuprolide 6-month trial (pqac-00000007) | Safety surveillance includes overall adverse events, injection-site reactions, and formulation-specific tolerability; in the 6-month leuprolide trial, no discontinuations due to adverse events occurred (pqac-00000007) | MAXO: endocrine therapy, gonadotropin-releasing hormone agonist therapy |


*Table: This table summarizes current treatment options for central precocious puberty, focusing on GnRH agonist formulations and the available phase 3 leuprolide acetate 6-month depot data. It also includes treatment goals, safety considerations, and suggested MAXO-aligned action terms for knowledge-base annotation.*